Simply Politics & News

[basserdan]

Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19

New Microbes and New Infections
Volume 43, September 2021, 100924

1)A.D.Santin - Department of Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT, USA
2)D.E.Scheim - US Public Health Service, Inactive Reserve, Blacksburg, VA, USA
3)P.A.McCullough - Texas A & M College of Medicine, Dallas, TX, USA
4)M.Yagisawa - Omura Satoshi Memorial Institute, Infection Control Research Center, Kitasato University, Tokyo, Japan
5)T.J.Borody - Centre for Digestive Diseases, New South Wales, Australia

Abstract

In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world’s most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

Continued below:

https://www.sciencedirect.com/science/article/pii/S2052297521000883